Medication · Also: Mounjaro, Zepbound

Tirzepatide

A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management.

A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management.

Also known as: Mounjaro, Zepbound

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1. The FDA has approved it for type 2 diabetes (Mounjaro) and for chronic weight management (Zepbound).

It is administered as a once-weekly injection, with dosing and follow-up managed by a prescriber.

Related terms

GLP-1

A class of medicines that mimic the gut hormone GLP-1 to lower blood sugar and reduce appetite.

Semaglutide

A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.

Mounjaro

A brand of injectable tirzepatide FDA-approved to treat type 2 diabetes.

Zepbound

A brand of injectable tirzepatide FDA-approved for chronic weight management.

Source

DailyMed: Tirzepatide

← Back to full glossary